Cost-effectiveness of oral nirmatrelvir/ritonavir in patients at high risk for progression to severe COVID-19 in the United States

Nirmatrelvir/ritonavir (NMV/r) is an orally administered antiviral indicated for the outpatient treatment of patients with mild-to-moderate COVID-19 at high risk for disease progression to severe illness. We estimated the cost-effectiveness of NMV/r versus best supportive care for patients with mild-to-moderate COVID-19 at high risk for progression to severe illness from a US health sector perspective.

Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: Josh Carlson, Volker Foos, Adam Kasle, Tendai Mugwagwa, Florin Draica, Timothy Lee Wiemken, Jennifer L. Nguyen, Ashley Cha-Silva, Kristen Migliaccio-Walle, Mendy Dzingina Source Type: research